Hearscape
← Organizations
Company

Eli Lilly and Company

Company-level hearing-loss landscape profile across checked programs, evidence quality, modalities, indications, and open data checks.

All ProgramsTherapeuticsDevices
Open filtered programs
Programs
5
linked to organization
Strong Evidence
2
2 status confirmed
Details Checked
5
0 open data checks
Company / Institution Links
5 / 0
industry vs non-industry records
Competitive Density
7
Pipeline Velocity
28
Completion Signal
0

Programs by Stage

Preclinical2
Phase 1/21
Phase 22

Trial / Program Status

Active2
Discontinued1
Unknown2

Modality Mix

Gene Therapy4
Small Molecule1

Indication Coverage

Hearing Loss5
Sensorineural Hearing Loss4
Genetic Hearing Loss3
Auditory Neuropathy1
OTOF-Related Hearing Loss1
Vestibular Schwannoma1

Program Types

Therapeutic5

Population Tags

adult3
genetic3
pediatric3
congenital2
pre-lingual2
bilateral1
hearing-adjacent1
mild-to-moderate1
older-adult1
otof-dfnb91

Strong-Evidence Records

2 records
AK-OTOF by Eli Lilly and Akouos
Strong evidence
Gene TherapyPhase 2Active

AAV-mediated OTOF gene replacement is delivered to the cochlea to restore otoferlin function in genetic hearing loss.

AK-antiVEGF by Eli Lilly and Akouos
Strong evidence
Gene TherapyPhase 1/2Active

AAVAnc80 vector-based therapeutic protein expression program designed to deliver anti-VEGF expression locally for unilateral vestibular schwannoma, with potential to preserve or improve hearing by modulating vestibular schwannoma biology.

Data checks: vestibular-schwannoma-hearing-adjacent

Checked Records With Caveats

5 checked · 0 open checks
LY3056480 by Audion Therapeutics
Details checked
Small MoleculePhase 2Discontinued

Intratympanic gamma-secretase inhibitor intended to promote cochlear hair-cell regeneration through Notch-pathway inhibition in sensorineural hearing loss.

Data checks: replaced-unclear-current-status-with-withdrawn-follow-on-trial, phase-2-withdrawn-before-enrollment
GJB2 hearing loss gene therapy by Eli Lilly
Details checked
Gene TherapyPreclinicalUnknown

AAV-based inner-ear gene therapy intended to restore GJB2 expression in supporting cells for connexin 26-related hearing loss.

Data checks: current-status-not-publicly-disclosed, route-not-publicly-disclosed
AK-CLRN1 by Eli Lilly
Details checked
Gene TherapyPreclinicalUnknown

AAV-based inner-ear gene therapy intended to restore CLRN1 expression for Usher syndrome type 3A-associated hearing loss.

Data checks: current-status-not-publicly-disclosed, route-not-publicly-disclosed